JDHIF:OTC-JD Health International Inc (USD)

COMMON STOCK | Pharmaceutical Retailers |

Last Closing

USD 3.125

Change

0.00 (0.00)%

Market Cap

USD 10.00B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-27 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
JDHIY JD Health International Inc

N/A

USD 12.19B
ALBHF Alibaba Health Information Tec..

N/A

USD 8.29B
RADLY Raia Drogasil SA ADR

N/A

USD 7.12B
CLCGY Clicks Group Ltd

N/A

USD 5.27B
SHPPF Shop Apotheke Europe N.V

N/A

USD 3.20B
SAEYY Shop Apotheke Europe N.V

N/A

USD 2.88B
NOTR Nowtransit Inc

N/A

USD 0.55B
ZRSEF Zur Rose Group AG

N/A

USD 0.46B
PNPL Pineapple Express

N/A

USD 0.01B
RLLVF Relevium Technologies Inc

N/A

USD 5.33M

ETFs Containing JDHIF

KEMQ KraneShares Emerging Mark.. 0.00 % 0.80 %

N/A

USD 0.02B
HSTC:LSE HSBC Hang Seng Tech UCITS.. 0.00 % 0.00 %

N/A

USD 3.39B
HSTE:LSE HSBC Hang Seng Tech UCITS.. 0.00 % 0.00 %

N/A

USD 3.39B

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -37.50% 53% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.50% 53% F 28% F
Trailing 12 Months  
Capital Gain -37.50% 53% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.50% 53% F 28% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -21.56% 21% F 12% F
Dividend Return -21.56% 21% F 11% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.04% 83% B 70% C-
Risk Adjusted Return -67.30% 13% F 9% A-
Market Capitalization 10.00B 95% A 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.